Skip to content

Effect of linalotide on intestinal dysfunction in patients with acute pancreatitis: a randomized controlled trial

Effect of linalotide on intestinal dysfunction in patients with acute pancreatitis: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080331
Enrollment
Unknown
Registered
2024-01-26
Start date
2024-07-28
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis

Interventions

linaclotide group:In the linaclotide group, participants received 1pill linaclotide oral once daily before breakfast in addition of routine treatment,and stopped taking it after 7 days.
Rhubarb group:50g raw rhubarb was added into 100ml warm boiled water, twice a day, orally) on the basis of conventional treatment

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Adult patients with AP (aged 18–75 years) were recruited. The time from AP onset to enrollment was restricted to 48 h. Participants complicated with GI dysfunction, which was defined as score of gut dysfunction (SGD) =5. Signed informed consent.

Exclusion criteria

Exclusion criteria: pregnant women,have already participated in other clinical trials,malignancy,chronic pancreatitis,peptic ulcer,mechanical intestinal obstruction,Inflammatory bowel diseases and other diseases which can cause chronic abdominal pain,patients with organ failure(score of Marshall =2),and patients who didn't sign informed consent.

Design outcomes

Primary

MeasureTime frame
score of gut dysfunction;

Secondary

MeasureTime frame
D-lactic acid;pocalcitonin;damine oxidase;C-reactive protein;tumour necrosis factor-a;interleukin-6;interleukin-1 beta;the composition of gut microbiota;total enteral nutrition tolerance rate ;the number of days that can tolerate total enteral nutrition;the score of abdominal pain;Utilization rate of anodynes during the course of the disease;Incidence of infection during the course of the disease;incidence of transient or persistent organ failure after admission;the rate of minimally invasive medical intervention or surgical intervention;proportion of various severity of pancreatitis;the rate of transfering to ICU;total hospitalization days;drug taste score;

Countries

China

Contacts

Public ContactHuifang Xiong

The First Affiliated Hospital of Nanchang University

happyjenny8485@126.com+86 189 7005 6474

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026